# A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

> **NCT00090220** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3819 (actual)

## Conditions studied

- Healthy Adult Female Participants
- Prevention
- Papillomavirus Infection
- Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

## Interventions

- **BIOLOGICAL:** Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00090220
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-16
- **Primary completion:** 2009-05-21
- **Final completion:** 2015-11-12
- **Target enrollment:** 3819 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090220, "A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00090220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*